Extractables and leachables requirements are evolving with draft ICH Q3E. Learn how companies can prepare for future E&L regulatory expectations.
阅读更多
The European Medicines Agency (EMA) has adopted a Reflection Paper on the Qualification of Non-Mutagenic Impurities (EMA/CHMP/4299/2026), introducing a new scientific framework for the safety assessment of non-mutagenic impurities in medicinal products.
阅读更多
Explore how Environmental Risk Assessment (ERA) helps ensure medicines heal us without harming the planet, balancing healthcare advances with ecological preservation.
阅读更多
New guideline from the European Medicines Agency (EMA) on the Environmental Risk Assessment of medicinal products for human use, accepted on February 15 and set to come into effect on September 1, 2024, stipulates that an ERA report will be required for all new applications for marketing authorization of medicinal products for human use.
阅读更多
